Skip to main content

Table 1 FDA approved PARP inhibitors for clinical use and associated indications

From: The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

PARP inhibitorClinical indications
OlaparibMaintenance therapy for platinum sensitive, recurrent, BRCA mutated ovarian cancer after ≥ 3 prior chemo regimens
Maintenance therapy for platinum sensitive, recurrent, epithelial ovarian, fallopian, and peritoneal cancer with confirmed or suspected BRCA mutations
Treatment of metastatic, HER2 negative, BRCA mutated breast cancer who previously received chemotherapy
Treatment of metastatic, BRCA mutated, pancreatic cancer
RucaparibTreatment of platinum sensitive, recurrent ovarian, fallopian, and peritoneal cancer
NiraparibMaintenance therapy for platinum sensitive, recurrent ovarian, fallopian, and peritoneal cancer
TalazoparibTreatment of BRCA mutated, HER2 negative, advanced breast cancer